Sign up to access all valuation multiples
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
2020
45
Last FY Revenue $7.0M
Last FY EBITDA -$68.7M
$480M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Evommune reported revenue of $7.0M and EBITDA of -$68.7M.
Evommune expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Evommune valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $7.0M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$68.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -982% | XXX | XXX | XXX |
| EBIT | XXX | -$70.0M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1000% | XXX | XXX | XXX |
| Net Profit | XXX | -$66.8M | XXX | XXX | XXX |
| Net Margin | XXX | -954% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Evommune has current market cap of $556M, and EV of $480M.
As of December 17, 2025, Evommune's stock price is $18.
See Evommune trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $480M | $556M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialEvommune's trades at 68.6x EV/Revenue multiple, and -7.0x EV/EBITDA.
See valuation multiples for Evommune and 15K+ public compsAs of December 17, 2025, Evommune has market cap of $556M and EV of $480M.
Equity research analysts estimate Evommune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Evommune's P/E ratio is not available.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $556M | XXX | $556M | XXX | XXX | XXX |
| EV (current) | $480M | XXX | $480M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 68.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -7.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -6.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -8.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEvommune's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.7M for the same period.
Evommune's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Evommune's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Evommune and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | -6% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -982% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 918% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1100% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Evommune acquired XXX companies to date.
Last acquisition by Evommune was XXXXXXXX, XXXXX XXXXX XXXXXX . Evommune acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Evommune founded? | Evommune was founded in 2020. |
| Where is Evommune headquartered? | Evommune is headquartered in United States of America. |
| How many employees does Evommune have? | As of today, Evommune has 45 employees. |
| Who is the CEO of Evommune? | Evommune's CEO is Mr. Luis C. Pena. |
| Is Evommune publicy listed? | Yes, Evommune is a public company listed on NYS. |
| What is the stock symbol of Evommune? | Evommune trades under EVMN ticker. |
| When did Evommune go public? | Evommune went public in 2025. |
| Who are competitors of Evommune? | Similar companies to Evommune include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Evommune? | Evommune's current market cap is $556M |
| Is Evommune profitable? | Yes, Evommune is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
